Novartis awarded 2014 UK Prix Galien for Bexser
AstraZeneca, Bristol-Myers Squibb and Boehringer Ingelheim are among the finalists for the 2016 UK Prix Galien Awards.
The companies will line-up alongside Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda for a shot at one of the prestigious prizes later this year.
These will be awarded in just three categories – well-established innovative product, orphan product and the inaugural excellence in real world evidence.
Entry to the latter is only open to medicines that have previously won or received a commendation at the UK Prix Galien Awards, and this year Astellas, Celgene, MSD, Novartis and Sanofi Genzyme are in the running for the prize.
Karen Westaway, chief executive of ValueBase (new owners of Prix Galien’s UK franchise), said: “We are particularly proud to become the first Prix Galien franchise to recognise excellence in real world evidence, which is becoming an increasingly important factor in the uptake of new innovations.
“This is an exciting new category and it will be fascinating to see how innovations that have previously impressed Prix Galien judges have fared in this crucial area.”
Westaway added: “The bottom line, however, is simple: the strong line-up of finalists – the biggest in the history of UK Prix Galien – is itself ‘real world evidence’ of the rich vein of innovation that runs through the UK pharmaceutical industry.”
The innovative and orphan product awards have been running since the UK Prix Galien was established in 1970, with the 2014 top places going to Bexsero, Novartis’ breakthrough meningitis vaccine, and Janssen’s Sirturo, the first tuberculosis medication to be approved in four decades.
Competing this year for the prestigious bi-annual medals are Alexion, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chiesi, Janssen, Novartis, Otsuka and Takeda.
- For further details on the awards and the finalists visit www.prixgalien.co.uk
Innovative Product Award 2016 finalists
| Generic Name | Brand Name | Company | Indication (shortened) |
| vedolizumab | Entyvio | Takeda | Ulcerative Colitis and Crohn’s Disease |
| sacubitril/ valsartan | Entresto | Novartis | Symptomatic chronic heart failure with reduced ejection fraction |
| ibrutinib | Imbruvica | Janssen | MCL, CLL, WM |
| sebelipase alfa | Kanuma | Alexio | Lysosomal acid lipase deficiency (LAL-D) |
| nivolumab | Opdivo | BMS | Melanoma, lung cancer and renal cell carcinoma |
| idarucizumab | Praxbind | Boehringer Ingelheim | Anticoagulation reversal |
| osimertinib | Tagrisso | AstraZeneca | Non-small cell lung cancer (NSCLC) |
Orphan Product Award 2016 finalists
| Generic Name | Brand Name | Company | Indication (shortened) |
| corneal epithelial cells | Holoclar | Chiesi | Ex vivo expanded autologous human corneal epithelial cells |
| tolvaptan | Jinarc | Otsuka | Polycystic kidney disease |
| nintedanib | Ofev | Boehringer Ingelheim | Idiopathic pulmonary fibrosis |
| asfotase alfa | Strensiq | Alexion | paediatric-onset hypophosphatasia (HPP) – bone manifestations |
Real World Evidence Award 2016 finalists
| Generic Name | Brand Name | Company | Indication (shortened) |
| fidaxomicin | Dificlir | Astellas | Clostridium dificile infection |
| sitagliptin | Januvia | MSD | Type 2 Diabetes Mellitus |
| alglucosidase alfa | Myozyme | Sanofi Genzyme | Pompe Disease |
| azacitidine | Vidaza | Celgene | Myslodysplastic Syndrome |
| omalizumab | Xolair | Novartis | Sever persistent allergic asthma |